Searle’s DayPro
Executive Summary
Two years of additional market exclusivity for Searie's nonsteroidal anti-inflammatory drug DayPro (oxaprozin) would be provided under legislation introduced Nov. 19 in the Senate (S 1734) by Sens. Simon (D-Ill.), Hatch (R-Utah) and Moseley-Braun (D-Ill.) and in the House (HR 3552) by Rep. Collins (D-Ill.). Searle is based in Chicago. The additional exclusivity for the off-patent drug is being sought to compensate for the time that elapsed between Searle's NDA submission Aug. 10, 1982 and approval of DayPro Oct. 29, 1992.